

Adalimumab, Infliximab and Etanercept Biosimilars Global Market To Grow At Rate Of 41% Through 2026

*The Business Research Company's
Adalimumab, Infliximab And Etanercept
Biosimilars Global Market Report 2022:
Market Size, Trends, And Forecast To 2026*

LONDON, GREATER LONDON, UK, June 21, 2022 /EINPresswire.com/ --

According to 'Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026'

published by The Business Research Company, the adalimumab, infliximab and etanercept biosimilars market size is expected to grow from \$3.10 billion in 2021 to \$4.76 billion in 2022 at a compound annual growth rate (CAGR) of 53.4%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. As per TBRC's adalimumab, infliximab and etanercept biosimilars market research the market is expected to reach \$18.61 billion in 2026 at a CAGR of 40.6%. The patent expiry of branded biologic drugs such as Humira, Enbrel and Remicade will drive the adalimumab, infliximab and etanercept biosimilars market growth.

Want to learn more on the adalimumab, infliximab and etanercept biosimilars market growth? Request for a Sample now:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=2866&type=smp>

The adalimumab, infliximab and etanercept biosimilars market consists of sales of adalimumab, infliximab and etanercept biosimilar drugs by the companies that manufacture these biosimilars. Adalimumab, infliximab and etanercept biosimilar molecules are bioequivalent to original reference molecules such as Humira, Remicade and Enbrel, respectively.

Global [Adalimumab, Infliximab and Etanercept Biosimilars Market Trends](#)

The brand versions of biosimilar drugs are of high costs, which are now being replaced with



The Business
Research Company

Adalimumab, Infliximab And Etanercept Biosimilars
Global Market Report 2022: Market Size, Trends, And
Forecast To 2026

biosimilar versions upon their patent's expiry. The cost of branded biologic drugs almost doubled in recent years.

Global [Adalimumab, Infliximab and Etanercept Biosimilars Market Segments](#)

The global adalimumab, infliximab and etanercept biosimilars market is segmented:

By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others),
Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo)

By Application: Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis,
Ankylosing Spondylitis, Plaque Psoriasis, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

By Geography: The global adalimumab, infliximab and etanercept biosimilars market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read more on the global adalimumab, infliximab and etanercept biosimilars market report at:

<https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report>

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2022 is one of a series of new reports from The Business Research Company that provides adalimumab, infliximab and etanercept biosimilars market overviews, adalimumab, infliximab and etanercept biosimilars market analysis and forecasts market size and growth for the global adalimumab, infliximab and etanercept biosimilars market, adalimumab, infliximab and etanercept biosimilars market share, adalimumab, infliximab and etanercept biosimilars market segments and geographies, adalimumab, infliximab and etanercept biosimilars market players, adalimumab, infliximab and etanercept biosimilars market leading competitor revenues, profiles and market shares. The adalimumab, infliximab and etanercept biosimilars market report identifies top countries and segments for opportunities and strategies based on market trends and key competitors' approaches.

TBRC's Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2022 includes information on the following:

Data Segmentations: Market Size, Global, By Region and Country, Historic and Forecast, and Growth Rates for 60 Geographies

Key Market Players: Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd and Glenmark pharmaceuticals.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

And so much more.

Looking for something else? Here is a list of similar reports by The Business Research Company:

Pegfilgrastim Biosimilars Market 2022

<https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market>

Biosimilar Lymphocyte Modulator Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/biosimilar-lymphocyte-modulator-global-market-report>

Biosimilar Therapeutic Peptides Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptides-global-market-report>

About [The Business Research Company?](#)

The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

The Business Research Company

Email: info@tbrc.info

Follow us on LinkedIn: <https://bit.ly/3b7850r>

Follow us on Twitter: <https://bit.ly/3b1rmjS>

Check out our Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/577755433>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.